Court Deals a Blow to Pharma by Excluding Off-Label Drugs From Part D Reimbursement

by Jason M. Brocks , Legal Analyst, Bloomberg Law

Pharmaceutical companies may begin to rethink their pipeline and marketing strategies in light of the U.S. District Court’s highly technical analysis of the language of the Medicare law. The court’s opinion resulted in a denial of reimbursement to a Medicare Part D beneficiary for a drug that had been prescribed to him by his doctor.


Bloomberg BRIEF Newsletters